news
Project HOPE Presents Dr. Lechleiter, Lilly with Global Health Partner Award
12 June 2012 | By Eli Lilly and Company
Inaugural award recognizes life-changing impact of 53-year partnership...
List view / Grid view
Eli Lilly & Company
news
Lilly expands strategic partnership with Novast to serve chinese patients with high-quality branded generic medicines
12 June 2012 | By Eli Lilly and Company
Lilly will increase equity position in Novast by $20 million...
news
Lilly and Incyte’s oral JAK1 and JAK2 inhibitor, Baricitinib, showed positive results in Phase IIb study
Eli Lilly and Company and Incyte Corporation announced the presentation of 12-week results from a Phase IIb study of baricitinib, formerly LY3009104 (INCB28050), an orally available janus kinase (JAK) inhibitor, in patients with active rheumatoid arthritis (RA).
news
Lilly and Boehringer Ingelheim present data at the 72nd American Diabetes Association Scientific Sessions® from Phase II studies comparing investigational novel basal insulin to insulin glargine
11 June 2012 | By Boehringer Ingelheim
Eli Lilly and Company and Boehringer Ingelheim announced results from two Phase II studies...
news
William Kaelin Jr. elected to Lilly Board of Directors
6 June 2012 | By Eli Lilly and Company
The Board of Directors of Eli Lilly and Company has elected William G. Kaelin Jr., M.D. as a new member...
news
Boehringer Ingelheim and Lilly to feature 30 presentations on type 1 and type 2 diabetes
5 June 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) are pleased to announce that less than two years after forming a strategic alliance aimed at bringing new treatments to patients with diabetes, the companies will present 30 abstracts across three compounds and three classes of medicine at the 72nd American…
news
Phase III study: patients with most common type of lung cancer lived longer with ALIMTA-based continuation maintenance therapy
4 June 2012 | By Eli Lilly and Company
Overall survival data from PARAMOUNT study submitted to FDA...
news
Lung cancer study showed encouraging results for ALIMTA-based regimens and full-dose radiation
4 June 2012 | By Eli Lilly and Company
Eli Lilly and Company announced results of a Phase II trial evaluating ALIMTA®...
news
New data showed LIVALO® (pitavastatin) met primary endpoint of LDL-C reduction when compared with pravastatin
31 May 2012 | By Eli Lilly and Company
Results of the PREVAIL U.S. study...
news
Lilly’s commitment to global innovation reinforced with opening of new diabetes-focused research and development center in Shanghai
30 May 2012 | By Eli Lilly and Company
Eli Lilly & Company opened the LCRDC...
news
Jentadueto™ tablets recommended for approval in the treatment of adults with Type 2 Diabetes in Europe
25 May 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company has received a positive opinion from the EMA...
news
New Phase 3 data for Tradjenta® (linagliptin) tablets
24 May 2012 | By Eli Lilly and Company
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced Phase 3 study results for linagliptin 5 mg once-daily, which showed significant hemoglobin A1c (HbA1c or A1C) reduction of 0.88 percent compared to 0.24 percent in the placebo group (p=0.0002) at 24 weeks in black or African…
news
Lilly Diabetes presents Phase II blood pressure and heart rate data
22 May 2012 | By Eli Lilly and Company
Phase II trial used ambulatory blood pressure monitoring to evaluate blood pressure and heart rate for dulaglutide...
news
Updates on three of six ongoing Phase III Ramucirumab trials to be presented
14 May 2012 | By Eli Lilly and Company
Eli Lilly and Company will present data from several molecules...
news
Lilly Oncology to highlight final results for Phase III study in most common form of lung cancer
14 May 2012 | By Eli Lilly and Company
Eli Lilly and Company will present data from more than 25 studies...
